{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T06:23:59Z","timestamp":1787207039049,"version":"build-2736575974"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as an important therapy in heart failure (HF). However, their safety and efficacy in elderly patients remain underexplored, as this group is often underrepresented in clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study aimed to evaluate safety outcomes and describe changes in clinical parameters following initiation of SGLT2 inhibitors in elderly Malaysian patients with heart failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicentre, single-arm, retrospective cohort study was conducted from January to December 2023 at two Malaysian hospitals. Patients aged \u226565 years initiated on empagliflozin or dapagliflozin were included. Safety outcomes assessed were acute kidney injury (AKI), orthostatic hypotension, genitourinary infections, hypoglycemia, volume depletion, and diabetic ketoacidosis (DKA). Efficacy outcomes included changes in left ventricular ejection fraction (LVEF), glycated haemoglobin (HbA1c), estimated glomerular filtration rate (eGFR), and New York Heart Association (NYHA) class. Descriptive statistics and chi-square tests were applied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 126 patients (median age 70 years), AKI was the most frequent adverse event (12.1%), followed by orthostatic hypotension (3.0%) and urinary tract infection (1.5%). More than half (51.4%) showed LVEF improvement, while 38.2% of diabetic patients achieved better HbA1c control. Renal function improved or was preserved in 40.7%, and 21.4% demonstrated NYHA class improvement. Significant associations were observed between CKD and AKI (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003), and between systolic BP \u2264140\u2005mmHg and both eGFR improvement (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.034) and NYHA class improvement (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.029).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this retrospective cohort, SGLT2 inhibitor use was associated with observed improvements in selected cardiometabolic and functional parameters, with acute kidney injury being the most frequently recorded adverse event. However, given the single-arm retrospective design and the absence of a comparator group, these observed changes cannot be definitively attributed to SGLT2 inhibitor therapy alone and should therefore be interpreted as associations rather than evidence of a causal treatment effect. Careful clinical monitoring remains essential, particularly in patients with underlying renal impairment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1882576","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T05:28:49Z","timestamp":1787203729000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety &amp; efficacy of sodium glucose co-transport 2 (SGLT2) inhibitors in elderly patients with heart failure"],"prefix":"10.3389","volume":"13","author":[{"given":"Anis Nabila","family":"Mohamad","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Hospital Jitra","place":["Kedah, Malaysia"]},{"name":"Faculty of Pharmacy, University Kebangsaan Malaysia","place":["Kuala Lumpur, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandini Menon","family":"Premakumar","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University Kebangsaan Malaysia","place":["Kuala Lumpur, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Faiz","family":"Zaihan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hospital Shah Alam","place":["Selangor, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suharzelim","family":"Abu Bakar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Hospital Sultan Idris Shah","place":["Serdang, Selangor, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shairyzah","family":"Ahmad Hisham","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Nottingham Malaysia","place":["Semenyih, Selangor, Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jacasi.2024.01.013","article-title":"Epidemiology and burden of heart failure in Asia","volume":"4","author":"Feng","year":"2024","journal-title":"JACC Asia"},{"key":"B3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure","volume":"3","author":"Savarese","year":"2017","journal-title":"Card Fail Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.cjca.2016.05.005","article-title":"Heart failure in older adults","volume":"32","author":"Butrous","year":"2016","journal-title":"Can J Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.11909\/j.issn.1671-5411.2021.03.009","article-title":"Heart failure in the elderly","volume":"18","author":"Diez-Villanueva","year":"2021","journal-title":"J Geriatr Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.jchf.2024.02.021","article-title":"Aging in heart failure: embracing biology over chronology: JACC family series","volume":"12","author":"Goyal","year":"2024","journal-title":"JACC Heart Fail"},{"key":"B7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.5334\/gh.1108","article-title":"Trends for readmission and mortality after heart failure hospitalisation in Malaysia, 2007 to 2016","volume":"17","author":"Lim","year":"2022","journal-title":"Glob Heart"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21315\/mjms2024.31.4.1","article-title":"Healthy ageing in Malaysia by 2030: needs, challenges and future directions","volume":"31","author":"Abdullah","year":"2024","journal-title":"Malays J Med Sci"},{"key":"B9","volume-title":"Clinical Practice Guidelines: Management of Heart Failure","year":"2023"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"afad254","DOI":"10.1093\/ageing\/afad254","article-title":"Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis","volume":"53","author":"Aldafas","year":"2024","journal-title":"Age Ageing"},{"key":"B12","doi-asserted-by":"publisher","first-page":"106396","DOI":"10.1016\/j.phrs.2022.106396","article-title":"SGLT2-inhibitors Are effective and safe in the elderly: the SOLD study","volume":"183","author":"Lunati","year":"2022","journal-title":"Pharmacol Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.1","article-title":"KDIGO Clinical practice guideline for acute kidney injury","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"B15","volume-title":"Clinical Practice Guidelines: Management of Type 2 Diabetes mellitus","year":"2020"},{"key":"B16","volume-title":"Clinical Practice Guidelines: Management of Hypertension","year":"2018"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3390\/clinpract13060116","article-title":"Improvement in left and right ventricular function after introduction of SGLT2 inhibitors in heart failure outpatients with reduced ejection fraction","volume":"13","author":"Alcidi","year":"2023","journal-title":"Clin Pract (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.pcd.2020.10.002","article-title":"Efficacy, renal safety and tolerability of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes: a real-world experience","volume":"15","author":"Tumminia","year":"2021","journal-title":"Prim Care Diabetes"},{"key":"B19","doi-asserted-by":"publisher","first-page":"111796","DOI":"10.1016\/j.diabres.2024.111796","article-title":"Impact of age on eGFR dynamics following sodium-glucose cotransporter 2 inhibitor therapy: a real-world study","volume":"214","author":"An","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1111\/dom.15193","article-title":"Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"25","author":"Rigato","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"B21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4103\/ijem.IJEM_566_18","article-title":"Adverse effect profile and effectiveness of sodium glucose co-transporter 2 inhibitors (SGLT2i)\u2014a prospective real-world setting study","volume":"23","author":"Gill","year":"2019","journal-title":"Indian J Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1002\/ejhf.2707","article-title":"Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR-reduced","volume":"24","author":"Filippatos","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2025.09.023","article-title":"Impact of empagliflozin and dapagliflozin on sudden cardiac death: a systematic review and meta-analysis of adjudicated randomized evidence","author":"Matteucci","year":"2025","journal-title":"Heart Rhythm"},{"key":"B28","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/ejh.70155","article-title":"Oral anticoagulation after atrial fibrillation ablation: an updated systematic review and meta-analysis of 267 443 patients","volume":"116","author":"Matteucci","year":"2026","journal-title":"Eur J Haematol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1882576\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T05:28:51Z","timestamp":1787203731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1882576\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":28,"alternative-id":["10.3389\/fcvm.2026.1882576"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1882576","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"1882576"}}